{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:50:43Z","timestamp":1740163843399,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Post-progression survival affects overall survival (OS) in patients with HER2-negative advanced breast cancer (HER2-ABC); thus, the optimal choice of first-line chemotherapy (1LCT) remains controversial. We investigated patients with HER2-ABC focusing on their sensitivity to 1LCT. We retrospectively analyzed patients with HER2-ABC who received 1LCT between January 2011 and December 2016 in three participating institutions. We identified 149 patients in the shorter and 152 patients in the longer time to treatment failure (TTF) groups. The median OS was significantly longer in the longer TTF group (hazard ratio [HR] 0.44, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, log-rank). In the shorter TTF group, OS of patients who received paclitaxel plus bevacizumab (PB) therapy was significantly inferior to that of those who received chemotherapy other than PB (HR 2.57, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, log-rank), and subsequent eribulin therapy significantly improved OS from 1LCT initiation (Wilcoxon <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001); multivariate analyses showed that 1LCT PB therapy was an independent risk factor for poorer OS (HR 2.05, <jats:italic>P<\/jats:italic>\u2009=\u20090.003), while subsequent eribulin therapy was an independent prognostic factor for better OS (HR 0.56, <jats:italic>P<\/jats:italic>\u2009=\u20090.004). OS was significantly poorer in patients with HER2-ABC with a shorter duration of 1LCT, including PB therapy, while subsequent eribulin therapy improved OS.<\/jats:p>","DOI":"10.1038\/s41598-021-00711-x","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T11:03:37Z","timestamp":1635851017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8043-8608","authenticated-orcid":false,"given":"Shogo","family":"Nakamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9226-895X","authenticated-orcid":false,"given":"Junichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichiro","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"key":"711_CR1","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1200\/jco.2014.56.7479","volume":"32","author":"AH Partridge","year":"2014","unstructured":"Partridge, A. H. et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 32, 3307\u20133329. https:\/\/doi.org\/10.1200\/jco.2014.56.7479 (2014).","journal-title":"J. Clin. Oncol."},{"key":"711_CR2","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/jnci\/djp369","volume":"101","author":"KR Broglio","year":"2009","unstructured":"Broglio, K. R. & Berry, D. A. Detecting an overall survival benefit that is derived from progression-free survival. J. Natl. Cancer Inst. 101, 1642\u20131649. https:\/\/doi.org\/10.1093\/jnci\/djp369 (2009).","journal-title":"J. Natl. Cancer Inst."},{"key":"711_CR3","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/jco.2007.10.8407","volume":"26","author":"T Burzykowski","year":"2008","unstructured":"Burzykowski, T. et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J. Clin. Oncol. 26, 1987\u20131992. https:\/\/doi.org\/10.1200\/jco.2007.10.8407 (2008).","journal-title":"J. Clin. Oncol."},{"key":"711_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10549-015-3643-5","volume":"154","author":"G Adunlin","year":"2015","unstructured":"Adunlin, G., Cyrus, J. W. & Dranitsaris, G. Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis. Breast Cancer Res. Treat. 154, 591\u2013608. https:\/\/doi.org\/10.1007\/s10549-015-3643-5 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"711_CR5","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372, 724\u2013734. https:\/\/doi.org\/10.1056\/NEJMoa1413513 (2015).","journal-title":"N. Engl. J. Med."},{"key":"711_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","volume":"23","author":"A DeMichele","year":"2021","unstructured":"DeMichele, A. et al. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+\/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 23, 37. https:\/\/doi.org\/10.1186\/s13058-021-01409-8 (2021).","journal-title":"Breast Cancer Res."},{"key":"711_CR7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso, F. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol. 31, 1623\u20131649. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010 (2020).","journal-title":"Ann. Oncol."},{"key":"711_CR8","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/annonc\/mdw260","volume":"27","author":"S Delaloge","year":"2016","unstructured":"Delaloge, S. et al. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. Ann. Oncol. 27, 1725\u20131732. https:\/\/doi.org\/10.1093\/annonc\/mdw260 (2016).","journal-title":"Ann. Oncol."},{"key":"711_CR9","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1200\/jco.2010.31.5374","volume":"29","author":"A Gennari","year":"2011","unstructured":"Gennari, A. et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J. Clin. Oncol. 29, 2144\u20132149. https:\/\/doi.org\/10.1200\/jco.2010.31.5374 (2011).","journal-title":"J. Clin. Oncol."},{"key":"711_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.21873\/invivo.11473","volume":"33","author":"J Yamamura","year":"2019","unstructured":"Yamamura, J. et al. Response to first-line recurrence treatment influences survival in hormone receptor-positive, HER2-negative breast cancer: A multicenter study. In Vivo 33, 281\u2013287. https:\/\/doi.org\/10.21873\/invivo.11473 (2019).","journal-title":"In Vivo"},{"key":"711_CR11","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.21873\/invivo.11917","volume":"34","author":"S Nakamoto","year":"2020","unstructured":"Nakamoto, S., Watanabe, J., Ohtani, S., Morita, S. & Ikeda, M. Bevacizumab as first-line treatment for HER2-negative advanced breast cancer: Paclitaxel plus bevacizumab versus other chemotherapy. In Vivo 34, 1377\u20131386. https:\/\/doi.org\/10.21873\/invivo.11917 (2020).","journal-title":"In Vivo"},{"key":"711_CR12","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/sj.bjc.6604759","volume":"99","author":"B Sherrill","year":"2008","unstructured":"Sherrill, B. et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br. J. Cancer 99, 1572\u20131578. https:\/\/doi.org\/10.1038\/sj.bjc.6604759 (2008).","journal-title":"Br. J. Cancer"},{"key":"711_CR13","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/jco.2006.08.1935","volume":"25","author":"PA Tang","year":"2007","unstructured":"Tang, P. A., Bentzen, S. M., Chen, E. X. & Siu, L. L. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J. Clin. Oncol. 25, 4562\u20134568. https:\/\/doi.org\/10.1200\/jco.2006.08.1935 (2007).","journal-title":"J. Clin. Oncol."},{"key":"711_CR14","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1200\/jco.2007.11.8836","volume":"25","author":"M Buyse","year":"2007","unstructured":"Buyse, M. et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J. Clin. Oncol. 25, 5218\u20135224. https:\/\/doi.org\/10.1200\/jco.2007.11.8836 (2007).","journal-title":"J. Clin. Oncol."},{"key":"711_CR15","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/sj.bjc.6602858","volume":"93","author":"A Hackshaw","year":"2005","unstructured":"Hackshaw, A., Knight, A., Barrett-Lee, P. & Leonard, R. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br. J. Cancer 93, 1215\u20131221. https:\/\/doi.org\/10.1038\/sj.bjc.6602858 (2005).","journal-title":"Br. J. Cancer"},{"key":"711_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299\u2013309. https:\/\/doi.org\/10.1038\/s41586-019-1730-1 (2019).","journal-title":"Nature"},{"key":"711_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121193","author":"PF Lainetti","year":"2020","unstructured":"Lainetti, P. F., Leis-Filho, A. F., Laufer-Amorim, R., Battazza, A. & Fonseca-Alves, C. E. Mechanisms of resistance to chemotherapy in breast cancer and possible targets in drug delivery systems. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics12121193 (2020).","journal-title":"Pharmaceutics"},{"key":"711_CR18","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666\u20132676. https:\/\/doi.org\/10.1056\/NEJMoa072113 (2007).","journal-title":"N. Engl. J. Med."},{"key":"711_CR19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40261-019-00790-9","volume":"39","author":"E Ciruelos","year":"2019","unstructured":"Ciruelos, E., P\u00e9rez-Garc\u00eda, J. M., Gavil\u00e1, J., Rodr\u00edguez, A. & de la Haba-Rodriguez, J. Maintenance therapy in HER2-negative metastatic breast cancer: A new approach for an old concept. Clin. Drug Investig. 39, 595\u2013606. https:\/\/doi.org\/10.1007\/s40261-019-00790-9 (2019).","journal-title":"Clin. Drug Investig."},{"key":"711_CR20","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/s1470-2045(16)30154-1","volume":"17","author":"C Zielinski","year":"2016","unstructured":"Zielinski, C. et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncol. 17, 1230\u20131239. https:\/\/doi.org\/10.1016\/s1470-2045(16)30154-1 (2016).","journal-title":"Lancet Oncol."},{"key":"711_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejca.2016.09.024","volume":"70","author":"D Miles","year":"2017","unstructured":"Miles, D. et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur. J. Cancer 70, 146\u2013155. https:\/\/doi.org\/10.1016\/j.ejca.2016.09.024 (2017).","journal-title":"Eur. J. Cancer"},{"key":"711_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098715","volume":"9","author":"S Ueda","year":"2014","unstructured":"Ueda, S. et al. Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients. PLoS ONE 9, e98715. https:\/\/doi.org\/10.1371\/journal.pone.0098715 (2014).","journal-title":"PLoS ONE"},{"key":"711_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JM Ebos","year":"2009","unstructured":"Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232\u2013239. https:\/\/doi.org\/10.1016\/j.ccr.2009.01.021 (2009).","journal-title":"Cancer Cell"},{"key":"711_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M P\u00e0ez-Ribes","year":"2009","unstructured":"P\u00e0ez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220\u2013231. https:\/\/doi.org\/10.1016\/j.ccr.2009.01.027 (2009).","journal-title":"Cancer Cell"},{"key":"711_CR25","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","volume":"91","author":"S Goel","year":"2011","unstructured":"Goel, S. et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91, 1071\u20131121. https:\/\/doi.org\/10.1152\/physrev.00038.2010 (2011).","journal-title":"Physiol. Rev."},{"key":"711_CR26","doi-asserted-by":"publisher","first-page":"6328","DOI":"10.1038\/s41598-021-85948-2","volume":"11","author":"S Nakamoto","year":"2021","unstructured":"Nakamoto, S. et al. Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer. Sci. Rep. 11, 6328. https:\/\/doi.org\/10.1038\/s41598-021-85948-2 (2021).","journal-title":"Sci. Rep."},{"key":"711_CR27","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/s0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes, J. et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377, 914\u2013923. https:\/\/doi.org\/10.1016\/s0140-6736(11)60070-6 (2011).","journal-title":"Lancet"},{"key":"711_CR28","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman, P. A. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 33, 594\u2013601. https:\/\/doi.org\/10.1200\/JCO.2013.52.4892 (2015).","journal-title":"J. Clin. Oncol."},{"key":"711_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","volume":"148","author":"C Twelves","year":"2014","unstructured":"Twelves, C. et al. Efficacy of eribulin in women with metastatic breast cancer: A pooled analysis of two phase 3 studies. Breast Cancer Res. Treat. 148, 553\u2013561. https:\/\/doi.org\/10.1007\/s10549-014-3144-y (2014).","journal-title":"Breast Cancer Res. Treat."},{"key":"711_CR30","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/annonc\/mdw203","volume":"27","author":"X Pivot","year":"2016","unstructured":"Pivot, X. et al. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann. Oncol. 27, 1525\u20131531. https:\/\/doi.org\/10.1093\/annonc\/mdw203 (2016).","journal-title":"Ann. Oncol."},{"key":"711_CR31","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida, T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br. J. Cancer 110, 1497\u20131505. https:\/\/doi.org\/10.1038\/bjc.2014.80 (2014).","journal-title":"Br. J. Cancer"},{"key":"711_CR32","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi, Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 105, 1334\u20131342. https:\/\/doi.org\/10.1111\/cas.12488 (2014).","journal-title":"Cancer Sci."},{"key":"711_CR33","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/cas.13392","volume":"108","author":"K Ito","year":"2017","unstructured":"Ito, K. et al. Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models. Cancer Sci. 108, 2273\u20132280. https:\/\/doi.org\/10.1111\/cas.13392 (2017).","journal-title":"Cancer Sci."},{"key":"711_CR34","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/bjc.2016.122","volume":"114","author":"S Ueda","year":"2016","unstructured":"Ueda, S. et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br. J. Cancer 114, 1212\u20131218. https:\/\/doi.org\/10.1038\/bjc.2016.122 (2016).","journal-title":"Br. J. Cancer"},{"key":"711_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10549-020-05626-1","volume":"181","author":"J Watanabe","year":"2020","unstructured":"Watanabe, J., Saito, M., Horimoto, Y. & Nakamoto, S. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: A single-institutional experience. Breast Cancer Res. Treat. 181, 211\u2013220. https:\/\/doi.org\/10.1007\/s10549-020-05626-1 (2020).","journal-title":"Breast Cancer Res. Treat."},{"key":"711_CR36","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12282-020-01067-2","volume":"27","author":"Y Miyoshi","year":"2020","unstructured":"Miyoshi, Y. et al. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician\u2019s choice-in the EMBRACE study. Breast Cancer 27, 706\u2013715. https:\/\/doi.org\/10.1007\/s12282-020-01067-2 (2020).","journal-title":"Breast Cancer"},{"key":"711_CR37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10549-017-4478-z","volume":"166","author":"J Watanabe","year":"2017","unstructured":"Watanabe, J., Hayashi, T., Tadokoro, Y., Nishimura, S. & Takahashi, K. Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: A review of a single institution. Breast Cancer Res. Treat. 166, 911\u2013917. https:\/\/doi.org\/10.1007\/s10549-017-4478-z (2017).","journal-title":"Breast Cancer Res. Treat."},{"key":"711_CR38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026 (2009).","journal-title":"Eur. J. Cancer"},{"key":"711_CR39","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 48, 452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244 (2013).","journal-title":"Bone Marrow Transplant."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00711-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00711-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00711-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:58:57Z","timestamp":1670086737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00711-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["711"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-00711-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"14 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author Shogo Nakamoto has received lecture fees from Chugai Pharmaceuticals, Eisai Co., Ltd., and Taiho Pharmaceuticals outside the submitted work; Junichiro Watanabe has received lecture fees from AstraZeneca, Chugai Pharmaceuticals, Daiichi-Sankyo, Eisai Co., Ltd., Eli-Lilly, Novartis Pharma, Pfizer, and Taiho Pharmaceuticals outside the submitted work; Shoichiro Ohtani has received lecture fees from AstraZeneca, Chugai Pharmaceuticals, Eli-Lilly, and Pfizer outside the submitted work; Satoshi Morita has received lecture fees from Chugai Pharmaceuticals outside the submitted work; Masahiko Ikeda has received lecture fees from AstraZeneca, Chugai Pharmaceuticals, Daiichi-Sankyo, Eisai Co., Ltd., Eli-Lilly, Kyowa Kirin, Pfizer, Nippon Kayaku, Novartis, Mundipharma, Celltrion Healthcare, and Sawai Pharmaceuticals outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21454"}}